RÉSUMÉ
BACKGROUND: In the randomized phase II REGOMA trial, regorafenib showed promising activity in patients with recurrent glioblastoma. We conducted a large, multicenter, prospective, observational study to confirm the REGOMA data in a real-world setting. PATIENTS AND METHODS: The major inclusion criteria were histologically confirmed diagnosis of glioblastoma according to the World Health Organization (WHO) 2016 classification and relapse after radiotherapy with concurrent/adjuvant temozolomide treatment, good performance status [Eastern Cooperative Oncology Group performance status (ECOG PS 0-1)] and good liver function. Regorafenib was administered at the standard dose of 160 mg/day for 3 weeks on/1 week off. Brain magnetic resonance imaging was carried out within 14 days before starting regorafenib and every 8-12 weeks. The primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS), objective response rate, disease control rate (DCR), safety and health-related quality of life. The Response Assessment in Neuro-Oncology (RANO) criteria were used for response evaluation and Common Terminology Criteria for Adverse Events (CTCAE) version 5 for assessment of adverse events (AEs). RESULTS: From September 2020 to October 2022, 190 patients with recurrent glioblastoma were enrolled from 30 cancer centers in Italy: their median age was 58.5 years [interquartile range (IQR) 53-67 years], 68% were male and 85 (44.7%) were in optimal clinical condition (ECOG PS 0). The number of patients taking steroids at baseline was 113 (60%); the second surgery was carried out in 39 (20.5%). O6-methylguanine-DNA methyltransferase (MGMT) was methylated in 80 patients (50.3%) and 147 (92.4%) of the patients analyzed had isocitrate dehydrogenase (IDH) wild type. The median follow-up period was 20 months (IQR 15.6-25.5 months). The median OS was 7.9 months ([95% confidence interval (CI) 6.5-9.2 months] and the median PFS was 2.6 months (95% CI 2.3-2.9 months). Radiological response was partial response and stable disease in 13 (7.3%) and 26 (14.6%) patients, respectively, with a DCR of 21.9%. The median number of regorafenib cycles per patient was 3 (IQR 2.0-4.0). Grade 3-4 drug-related adverse events were reported in 22.6% of patients. A dose reduction due to AEs was required in 36% of patients. No deaths were considered as treatment-related AEs. CONCLUSIONS: This large, real-world observational study showed similar OS with better tolerability of regorafenib in patients with relapsed glioblastoma compared with the REGOMA study.
Sujet(s)
Tumeurs du cerveau , Glioblastome , Récidive tumorale locale , Phénylurées , Pyridines , Humains , Glioblastome/traitement médicamenteux , Mâle , Femelle , Adulte d'âge moyen , Études prospectives , Pyridines/usage thérapeutique , Pyridines/pharmacologie , Sujet âgé , Phénylurées/usage thérapeutique , Phénylurées/pharmacologie , Tumeurs du cerveau/traitement médicamenteux , Italie , Adulte , Antinéoplasiques/usage thérapeutique , Antinéoplasiques/pharmacologie , Qualité de vie , Résultat thérapeutiqueRÉSUMÉ
We measured nuclear forward scattering spectra utilizing the (99)Ru transition, 89.571(3) keV, with a notably mixed E2/M1 multipolarity. The extension of the standard evaluation routines to include mixed multipolarity allows us to extract electric and magnetic hyperfine interactions from (99)Ru-containing compounds. This paves the way for several other high-energy Mössbauer transitions, E â¼ 90 keV. The high energy of such transitions allows for operando nuclear forward scattering studies in real devices.
RÉSUMÉ
The present study aimed at investigating whether the simultaneous evaluation of pharmacokinetic, pharmacogenetic and demographic factors could improve prediction on toxicity and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil (5FU)/leucovorin therapy. One hundred and thirty consecutive, B2 and C Duke's stage colorectal cancer patients were prospectively enrolled. 5FU pharmacokinetics was evaluated at the first cycle. Thymidylate synthase (TYMS) 5'UTR and 3'UTR polymorphisms and methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms were assessed in peripheral leukocytes. Univariate and multivariate analyses were applied to evaluate which variables could predict chemotherapy-induced toxicity, disease-free survival (DFS) and overall survival (OS). Multivariate analysis showed that: (a) low 5FU clearance was an independent predictive factor for severe toxicity (OR=7.32; P<0.0001); (b) high-5FU clearance predicted poorer DFS (HR=1.96; P=0.041) and OS (HR=3.37; P=0.011); (c) advanced age was associated with shorter DFS (HR=3.34; P=0.0008) and OS (HR=2.66; P=0.024); (d) the C/C genotype of the MTHFR C677T polymorphism was protective against grade 3-4 toxicity (P=0.040); (e) none of the TYMS polymorphisms could explain 5FU toxicity or clinical outcome.
Sujet(s)
Carcinomes/diagnostic , Carcinomes/traitement médicamenteux , Tumeurs colorectales/diagnostic , Tumeurs colorectales/traitement médicamenteux , Fluorouracil/usage thérapeutique , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Antimétabolites antinéoplasiques/administration et posologie , Antimétabolites antinéoplasiques/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Carcinomes/génétique , Carcinomes/mortalité , Traitement médicamenteux adjuvant , Tumeurs colorectales/génétique , Tumeurs colorectales/mortalité , Résistance aux médicaments antinéoplasiques/génétique , Effets secondaires indésirables des médicaments/diagnostic , Effets secondaires indésirables des médicaments/génétique , Femelle , Fluorouracil/administration et posologie , Génotype , Humains , Leucovorine/administration et posologie , Mâle , Methylenetetrahydrofolate reductase (NADPH2)/génétique , Adulte d'âge moyen , Polymorphisme de nucléotide simple , Pronostic , Analyse de survie , Thymidylate synthase/génétiqueRÉSUMÉ
BACKGROUND: Grade IV chemotherapy toxicity is defined as absolute neutrophil count <500/microL. The nadir is considered as the lowest neutrophil number following chemotherapy, and generally is not expected before the 7th day from the start of chemotherapy. The usual prophylactic dose of rHu-G-CSF (Filgrastim) is 300 microg/day, starting 24-48 h after chemotherapy until hematological recovery. However, individual patient response is largely variable, so that rHu-G-CSF doses can be different. The aim of this study was to verify if peripheral blood automated flow cytochemistry and flow cytometry analysis may be helpful in predicting the individual response and saving rHu-G-CSF. METHODS: During Grade IV neutropenia, blood counts from 30 cancer patients were analyzed daily by ADVIA 120 automated flow cytochemistry analyzer and by Facscalibur flow cytometer till the nadir. "Large unstained cells" (LUCs), myeloperoxidase index (MPXI), blasts, and various cell subpopulations in the peripheral blood were studied. At nadir rHu-G-CSF was started and 81 chemotherapy cycles were analyzed. Cycles were stratified according to their number and to two dose-levels of rHuG-CSF needed to recovery (300-600 vs. 900-1200 microg) and analyzed in relation to mean values of MPXI and mean absolute number of LUCs in the nadir phase. The linear regressions of LUCs % over time in relation to two dose-levels of rHu-G-CSF and uni-multivariate analysis of lymphocyte subpopulations, CD34(+) cells, MPXI, and blasts were also performed. RESULTS: In the nadir phase, the increase of MPXI above the upper limit of normality (>10; median 27.7), characterized a slow hematological recovery. MPXI levels were directly related to the cycle number and inversely related to the absolute number of LUCs and CD34(+)/CD45(+) cells. A faster hematological recovery was associated with a higher LUC increase per day (0.56% vs. 0.25%), higher blast (median 36.7/microL vs. 19.5/microL) and CD34(+)/CD45(+) cell (median 2.2/microL vs. 0.82/microL) counts. CONCLUSIONS: Our study showed that some biological indicators such as MPXI, LUCs, blasts, and CD34(+)/CD45(+) cells may be of clinical relevance in predicting individual hematological response to rHu-G-CSF. Special attention should be paid when nadir MPXI exceeds the upper limit of normality because the hematological recovery may be delayed.
Sujet(s)
Marqueurs biologiques tumoraux/métabolisme , Facteur de stimulation des colonies de granulocytes/usage thérapeutique , Tumeurs/thérapie , Adulte , Sujet âgé , Séparation cellulaire , Femelle , Filgrastim , Cytométrie en flux/méthodes , Humains , Immunophénotypage , Numération des leucocytes , Leucocytes/physiologie , Mâle , Adulte d'âge moyen , Tumeurs/métabolisme , Protéines recombinantesRÉSUMÉ
The adsorption of proteins is the first process to take place when a solid is immersed in a biological fluid; though not yet thoroughly understood at a molecular level, this process is also known to be strongly influenced by the presence of salt in solution or by pH changes. In the present work, poly-L-glutamic acid (PG) and poly-L-lysine (PL) were selected to mimic the behavior of some protein fragments. Their adsorption was investigated by infrared spectroscopy in various modes, both on planar and on divided (powder) surfaces of aluminum oxide. These two peptides were shown to have different behaviors when adsorbed from solutions with or without CaCl2 and at various pH values. Polarization modulation-reflection absorption infrared spectroscopy, applied in a special cell designed to characterize the solid surface in contact with the liquid, enabled the observation of the influence of pH and salts upon polypeptide adsorption. At pH values higher than 5 and in the presence of CaCl2 in solution, a net increase of the PG adsorbed amount is observed, whereas no such effect could be detected for PL. Specific interactions between the COO- groups on the side chains and the surface, or between those of two different molecules, was inferred. Interestingly, similar conclusions could be drawn for the surface of alumina powders contacted with solutions of PG and PL and characterized by attenuated total reflectance IR. This work demonstrates the potential for IR investigations of solid oxide-liquid interfaces combining the study of planar and finely divided surfaces.
Sujet(s)
Oxyde d'aluminium/composition chimique , Chlorure de calcium/composition chimique , Peptides/composition chimique , Protéines/composition chimique , Spectrophotométrie IR/méthodes , Adsorption , Chimie physique/méthodes , Concentration en ions d'hydrogène , Modèles chimiques , Nanostructures , Acide polyglutamique/composition chimique , Poudres , Spectroscopie infrarouge à transformée de Fourier , Propriétés de surfaceRÉSUMÉ
BACKGROUND: The relationship between 5-fluorouracil (5-FU) pharmacokinetics and toxicity following i.v. bolus administration has not been extensively studied. PATIENTS AND METHODS: One hundred and eighty-one patients on adjuvant therapy with 5-FU plus leucovorin for colorectal cancer were the study population. 5-FU pharmacokinetics was determined on day 2 of the first, third, and fifth cycles; type and the grade of adverse reactions were recorded on the next cycle. RESULTS: The 5-FU area under the curve (AUC) measured at the first cycle ranged between 146 and 1236 mg x min/l and was significantly correlated with drug dose, patients' body weight (BW) and gender, females having higher AUCs. These covariates explained only 23% of AUC variability. AUC and age were the only covariates which discriminated between toxic (grade > or =2) and nontoxic cycles (grade <2), with an optimal AUC cut-off value of 596 mg x min/l. Such a correlation was lost during the next cycles following dose reduction because of toxicity in 80 patients. CONCLUSIONS: A method for calculating the initial 5-FU dose is proposed which takes into account patient BW, gender and a target AUC of 596 mg x min/l. Nevertheless, it appears that a substantial part of 5-FU toxicity is not linked to pharmacokinetic factors and dose adjustments must still be on the basis of careful clinical surveillance.
Sujet(s)
Antimétabolites antinéoplasiques/effets indésirables , Antimétabolites antinéoplasiques/pharmacocinétique , Tumeurs colorectales/traitement médicamenteux , Démographie , Fluorouracil/effets indésirables , Fluorouracil/pharmacocinétique , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Aire sous la courbe , Traitement médicamenteux adjuvant , Femelle , Humains , Mâle , Adulte d'âge moyenRÉSUMÉ
BACKGROUND: Gemcitabine is a nucleoside analogue with proven activity in advanced and metastatic breast cancer. Its action is associated with a favourable toxicity profile which is mainly hematological. Its unique mechanism of action along with not overlapping toxicity is particularly useful both in combination treatment with other active drugs and a sequential therapy in the palliative setting. DESIGN: Phase II studies of gemcitabine performed over the last decade were reviewed. RESULTS AND CONCLUSIONS: Despite some conflicting results in some trials, gemcitabine confirmed to be a useful drug to treat this condition.
Sujet(s)
Tumeurs du sein/traitement médicamenteux , Désoxycytidine/analogues et dérivés , Anthracyclines/administration et posologie , Antimétabolites antinéoplasiques/usage thérapeutique , Tumeurs du sein/anatomopathologie , Traitement médicamenteux adjuvant , Essais cliniques de phase II comme sujet , Désoxycytidine/usage thérapeutique , Évolution de la maladie , Humains , Traitement néoadjuvant , Métastase tumorale , Taxoïdes/administration et posologie ,RÉSUMÉ
The adsorption of neutral glycine onto amorphous silica was investigated both theoretically and experimentally. DFT calculations were performed at the BLYP-631++G** level using a cluster approach. Several possible configurations involving the formation of H bonds between glycine and one, two, or three silanol groups (SiOH) were considered. The most favorable bonding of glycine with one silanol group (45 kJ mol(-1)) occurs through the COOH moiety, thus forming a cycle in which the CO group is an H-bond acceptor whereas the acidic OH group is an H-bond donor. With two or three silanol groups, additional H bonds are formed between the amine moiety and the silanol groups, which leads to an increased adsorption energy (70 and 80 kJ mol(-1) for two and three silanol groups, respectively). Calculated nu(CO), delta(HNH), and delta(HCH) values are sensitive to the adsorption mode. A bathochromic shift of nu(CO) as compared to the nu(CO) of free glycine (calculated in the 1755-1790 cm(-1) range) is found for glycine in interaction with silanol(s). The more H bonds are formed between the COOH moiety and silanol groups, the higher the bathochromic shift. For delta(HNH), no shift is found for glycine adsorbed on one and two silanol groups (where the amine is either not bound or an H-bond donor), whereas a bathochromic shift is calculated with three silanols when the amine moiety is an H-bond acceptor. Experimental FTIR spectra performed at room temperature for glycine adsorbed at 160 degrees C on Aerosil amorphous silica exhibit bands at 1371, 1423, 1630, and 1699 cm(-1). The experimental/calculated frequencies have their best correspondence for glycine adsorbed on two silanol groups. It is important to note that the forms giving the best correspondence to experimental frequencies are the most stable ones.
Sujet(s)
Glycine/composition chimique , Silice/composition chimique , Adsorption , Modèles théoriques , Spectroscopie infrarouge à transformée de FourierRÉSUMÉ
In this paper we addressed the expression of the HIV co-receptors CXCR-4 and CCR-5 in human thymocytes by phenotypic, molecular and functional approaches. Cytofluorimetric analysis disclosed that CXCR-4 was constitutively expressed by freshly isolated thymocytes (~10 000 molecules/cell in about 30% of thymocytes); the receptor was endowed with functional activity, as it mediated polarization, migration and intracellular Ca2+ increase in response to its ligand, SDF-1. On the contrary, CCR-5 expression in freshly isolated thymocytes was significantly lower (<4000 molecules/cell in less than 5% of the cells), and no functional response to CCR-5 agonists could be documented. Northern blot analysis of freshly isolated thymocytes showed high CXCR-4 mRNA levels, whereas the message for CCR-5 was barely detectable. On the other hand, a modest increase in the expression of CCR-5 was associated with in vitro thymocyte stimulation, and CCR-5 density at the cell surface attained CXCR-4 figures in most cases. None the less, no functional response to CCR-5 agonists could be documented in in vitro stimulated thymocytes. In vitro infection of thymocytes by CAT-expressing recombinant HIV bearing the envelope glycoproteins from different isolates showed that T-tropic strains, which use CXCR-4 as a co-receptor, were more efficient in infecting thymocytes than M-tropic strains, which preferentially use CCR-5. Altogether, these data indicate that expression of the major co-receptors involved in infection by M-tropic HIV strains is very poor in human thymocytes, and would suggest that thymocyte infection by M-tropic HIV strains may be a rare event in vivo.
Sujet(s)
Récepteurs CCR5/biosynthèse , Récepteurs CXCR4/biosynthèse , Récepteur VIH/biosynthèse , Sous-populations de lymphocytes T/effets des médicaments et des substances chimiques , Technique de Northern , Calcium/métabolisme , Cellules cultivées/effets des médicaments et des substances chimiques , Cellules cultivées/immunologie , Cellules cultivées/métabolisme , Chimiokine CCL4 , Chimiokine CCL5/pharmacologie , Chimiokine CXCL12 , Chimiokines CXC/pharmacologie , Enfant d'âge préscolaire , Femelle , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Protéine d'enveloppe gp120 du VIH/métabolisme , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/classification , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/physiologie , Humains , Immunophénotypage , Nourrisson , Nouveau-né , Transport des ions/effets des médicaments et des substances chimiques , Activation des lymphocytes , Protéines inflammatoires des macrophages/pharmacologie , Mâle , Récepteurs CCR5/effets des médicaments et des substances chimiques , Récepteurs CCR5/génétique , Récepteurs CCR5/physiologie , Récepteurs CXCR4/effets des médicaments et des substances chimiques , Récepteurs CXCR4/génétique , Récepteurs CXCR4/physiologie , Récepteur VIH/effets des médicaments et des substances chimiques , Récepteur VIH/génétique , Récepteur VIH/physiologie , Sous-populations de lymphocytes T/immunologie , Sous-populations de lymphocytes T/métabolisme , Thymus (glande)/cytologieRÉSUMÉ
Locus control region (LCR) sequences are involved in the establishment of open chromosomal domains. To evaluate the possibility of exploiting the human CD2 LCR to regulate gene expression by Moloney murine leukemia virus (Mo-MLV)-based retroviral vectors in T cells, it was included in vectors carrying the enhanced green fluorescence protein (EGFP) reporter gene; then transduction in vitro of lymphoid and nonlymphoid cell lines was performed. Deletion of the viral enhancer in the Mo-MLV long terminal repeat was necessary to detect LCR activity in the context of these retroviral vectors. It was found that a full-length (2.1 kb), but not a truncated (1.0 kb), CD2 LCR retained the ability to modulate reporter gene expression by Mo-MLV-derived retroviral vectors, leading to a homogeneous, unimodal pattern of EGFP expression that remained unmodified in culture over time, specifically in T-cell lines; on the other hand, viral titer was strongly reduced compared with vectors not carrying the LCR. Lentiviral vectors containing the CD2 LCR could be generated at higher titers and were used to analyze its effects on gene expression in primary T cells. Subcutaneous implantation of genetically modified cells in immunodeficient mice showed that retroviral vectors carrying the CD2 LCR conferred an advantage in terms of transgene expression in vivo, compared with the parental vector, by preventing the down-modulation of EGFP expression. These findings suggest a potential application of this LCR to increase gene expression by retroviral and lentiviral vectors in T lymphocytes.